Metamark Genetics Lands $22,000,000 Series B Financing

  • Feed Type
  • Date
    7/14/2010
  • Company Name
    Metamark Genetics
  • Mailing Address
    Undisclosed Cambridge, MA 02138
  • Company Description
    Metamark is a privately held oncology company focused on the development of function-based prognostic assays for early staged cancers. The MetamarkDx Prognostic Assays under development are based on Metamark’s proprietary Prognosis Determinants, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread.
  • Website
    http://www.metamarkgenetics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $22,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to expand Metamark’s research and development and clinical testing infrastructure, in addition to establishing its commercial organization.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.